---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-017115"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:51:31.777526+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate

## Summary
- Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.
- Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.
- Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.
- Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.
- Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price.

## SEC filing metadata
- accession: 0001493152-26-017115
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-017115
- JSON: https://secwatch.observer/filing/0001493152-26-017115.json
- Plain text: https://secwatch.observer/filing/0001493152-26-017115.txt

## Key facts
- Governance Changes
  Aspire Biopharma Holdings, Inc.: Filed a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, clarifying and restating provisions relating to designation and number of shares to 30,000 shares of Series A Convertible Preferred Stock (effective 2026-04-13).
  - Change: charter amendment
  - Effective: 2026-04-13
  source text: On April 13, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Amendment”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm
- Material Agreements
  Aspire Biopharma Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors (effective 2026-02-06).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Effective: 2026-02-06
  source text: on February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315226017115/0001493152-26-017115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.